PMVP

Company Overview — What Does PMV Pharmaceuticals, Inc. Do?

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey. PMV Pharmaceuticals, Inc. (PMVP) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO David H. Mack and employs approximately 50 people. With a market capitalization of $71M, PMVP is one of the notable companies in the Healthcare sector.

PMV Pharmaceuticals, Inc. (PMVP) Stock Rating — Reduce (April 2026)

As of April 2026, PMV Pharmaceuticals, Inc. receives a Reduce rating with a composite score of 35.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.PMVP ranks #2,471 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, PMV Pharmaceuticals, Inc. ranks #308 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

PMVP Stock Price and 52-Week Range

PMV Pharmaceuticals, Inc. (PMVP) currently trades at $1.30. The stock lost $0.03 (1.9%) in the most recent trading session. The 52-week high for PMVP is $1.84, which means the stock is currently trading -29.1% from its annual peak. The 52-week low is $0.81, putting the stock 61.1% above its annual trough. Recent trading volume was 100K shares, suggesting relatively thin trading activity.

Is PMVP Overvalued or Undervalued? — Valuation Analysis

PMV Pharmaceuticals, Inc. (PMVP) carries a value factor score of 10/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.66x, versus the sector average of 2.75x. The price-to-sales ratio is 8.91x, compared to 1.66x for the average Healthcare stock.

At current multiples, PMV Pharmaceuticals, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

PMV Pharmaceuticals, Inc. Profitability — ROE, Margins, and Quality Score

PMV Pharmaceuticals, Inc. (PMVP) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -75.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -67.7% versus the sector average of -33.1%.

The operating margin is -1206.7% (sector: -66.1%). Net profit margin stands at -1078.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -47.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

PMVP Debt, Balance Sheet, and Financial Health

PMV Pharmaceuticals, Inc. has a debt-to-equity ratio of 11.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 10.09x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $36M.

PMVP has a beta of 0.50, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for PMV Pharmaceuticals, Inc. is 51/100, reflecting average volatility within the normal range for its sector.

PMV Pharmaceuticals, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, PMV Pharmaceuticals, Inc. reported revenue of $8M and earnings per share (EPS) of $-1.48. Net income for the quarter was $-79M. Operating income came in at $-89M.

In FY 2025, PMV Pharmaceuticals, Inc. reported revenue of $6M and earnings per share (EPS) of $-1.48. Net income for the quarter was $-78M. Operating income came in at $-86M.

In Q3 2025, PMV Pharmaceuticals, Inc. reported revenue of $1M and earnings per share (EPS) of $-0.40. Net income for the quarter was $-21M. Revenue grew -43.4% year-over-year compared to Q3 2024. Operating income came in at $-23M.

In Q2 2025, PMV Pharmaceuticals, Inc. reported revenue of $2M and earnings per share (EPS) of $-0.41. Net income for the quarter was $-21M. Revenue grew -39.7% year-over-year compared to Q2 2024. Operating income came in at $-23M.

Over the past 8 quarters, PMV Pharmaceuticals, Inc. has demonstrated a growth trajectory, with revenue expanding from $3M to $8M. Investors analyzing PMVP stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

PMVP Dividend Yield and Income Analysis

PMV Pharmaceuticals, Inc. (PMVP) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

PMVP Momentum and Technical Analysis Profile

PMV Pharmaceuticals, Inc. (PMVP) has a momentum factor score of 51/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 48/100 reflects moderate short selling activity.

PMVP vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, PMV Pharmaceuticals, Inc. (PMVP) ranks #308 out of 838 stocks based on the Blank Capital composite score. This places PMVP in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing PMVP against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PMVP vs S&P 500 (SPY) comparison to assess how PMV Pharmaceuticals, Inc. stacks up against the broader market across all factor dimensions.

PMVP Next Earnings Date

No upcoming earnings date has been announced for PMV Pharmaceuticals, Inc. (PMVP) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy PMVP? — Investment Thesis Summary

The quantitative profile for PMV Pharmaceuticals, Inc. suggests caution. The quality score of 25/100 flags below-average profitability. The value score of 10/100 indicates premium valuation.

In summary, PMV Pharmaceuticals, Inc. (PMVP) earns a Reduce rating with a composite score of 35.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PMVP stock.

Related Resources for PMVP Investors

Explore more research and tools: PMVP vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PMVP head-to-head with peers: PMVP vs AZN, PMVP vs SLGL, PMVP vs VMD.